Clinical trials: Active Population
Pneumonia
Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an…
- Trial name
- PRISM-UDR (NCT03582007)
- Testing
- Murepavadin, One anti-pseudomonal antibiotic
- Where
- 7 sites in United States, Czechia and 2 more
- Volunteers
- 2 people
- Sponsor
- Polyphor Ltd.
Osteoporosis
A Dose-response Study With Strontium Malonate in Postmenopausal Women
The primary objective of the study is to compare dose-response effect of three dose levels of strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of treatment.
- Trial name
- NCT00409032
- Testing
- Strontium malonate
- Where
- 9 sites in Denmark, United Kingdom
- Volunteers
- 275 people
- Sponsor
- Osteologix
Type 2 Diabetes Mellitus
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of…
- Trial name
- NCT07112872
- Testing
- RO7795081, Semaglutide
- Where
- 46 sites in United States, Hungary and 2 more
- Volunteers
- 330 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus…
- Trial name
- NCT01030952
- Testing
- Nateglinide, Acarbose
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Overactive Bladder Syndrome
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodine (SPM 907) 4mg…
- Trial name
- NCT00220363
- Testing
- SPM 907
- Where
- Germany
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who…
- Trial name
- NCT00490971
- Testing
- Olanzapine, Paliperidone ER
- Where
- 78 sites in United States, Bulgaria and 14 more
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pediatric Heart Failure
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696.
- Trial name
- NCT02678312
- Testing
- LCZ696, Enalapril
- Where
- 98 sites in United States, Argentina and 27 more
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Colitis, Ulcerative, Inflammatory Bowel Diseases
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in participants with moderately to severely active Ulcerative Colitis (UC) and as…
- Trial name
- UNIFI (NCT02407236)
- Testing
- Ustekinumab IV, Ustekinumab SC
- Where
- 247 sites in United States, Australia and 21 more
- Volunteers
- 961 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis Vulgaris
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03308799
- Testing
- MC2-01 cream, Cal/BDP combination, Cream vehicle
- Where
- 3 sites in United States
- Volunteers
- 794 people
- Sponsor
- MC2 Therapeutics
Pulmonary Disease, Chronic Obstructive
Dose Finding Study in COPD
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
- Trial name
- NCT00122434
- Testing
- BEA 2180 BR, tiotropium
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
phase-1 study pneumococcal conjugate vaccine study in healthy adults
- Trial name
- NCT03549208
- Testing
- LBVE01, LBVE02, Prevnar13
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy Volunteer
A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects
This is a Phase I, single-center, three-arm, randomized, double-blind, active- and placebo-controlled study to investigate the effect of GDC-0449 on the QT/QTc interval in healthy female subjects of non-childbearing potential.
- Trial name
- NCT01173536
- Testing
- GDC-0449, moxifloxacin
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240121
- Testing
- Rifaximin EIR
- Where
- 72 sites in United States
- Volunteers
- 80 people
- Sponsor
- Bausch Health Americas, Inc.
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are…
- Trial name
- NCT01604343
- Testing
- Sirukumab
- Where
- 156 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,670 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
- Trial name
- NCT00160602
- Testing
- Certolizumab Pegol
- Where
- 70 sites in United States, Bulgaria and 13 more
- Volunteers
- 590 people
- Sponsor
- UCB Pharma
Healthy
Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction
The purpose of this study is to assess the safety of IW-6118 when administered as a single oral dose to patients undergoing third molar extraction. Efficacy will be assessed in an exploratory manner.
- Trial name
- NCT01107236
- Testing
- IW-6118, Naproxen Sodium
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03657719
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Prostate Cancer, Prostate Cancer Metastatic
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- NCT02105675
- Testing
- Dendritic Cells DCVAC/PCa, Docetaxel
- Where
- 10 sites in Czechia
- Volunteers
- 60 people
- Sponsor
- SOTIO a.s.
Hypertension
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor.
- Trial name
- NCT00351130
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.